Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma

被引:2
|
作者
Bajestani, Nojan [1 ]
Wu, Gavin [1 ]
Hussein, Ahmed [1 ]
Makary, Mina S. [2 ]
机构
[1] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, Dept Radiol, Div Vasc & Intervent Radiol, 395 W 12th Ave, Columbus, OH 43210 USA
关键词
hepatocellular carcinoma; locoregional therapy; immunotherapy; combination therapy; progression-free survival; overall survival; PERCUTANEOUS RADIOFREQUENCY ABLATION; INTERNAL RADIATION-THERAPY; RANDOMIZED CONTROLLED-TRIAL; TRANSARTERIAL CHEMOEMBOLIZATION; OPEN-LABEL; PHASE-III; SURGICAL RESECTION; MICROWAVE ABLATION; Y-90; MICROSPHERES; SYSTEMIC THERAPY;
D O I
10.3390/biomedicines12071432
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
More than 800,000 people worldwide are diagnosed with HCC (hepatocellular carcinoma) each year, with approximately 700,000 deaths alone occurring in that same year. Treatment of HCC presents complex therapeutic challenges, particularly in intermediate and advanced stages. LRTs such as transarterial chemoembolization (TACE) and ablations have been the mainstay treatment for early to intermediate-stage HCC, and systemic therapies are used to treat intermediate-late-stage HCC. However, novel literature describing combining LRT with systemic therapies has shown promising results. This review explores recent advances in both liver-directed techniques for hepatocellular carcinoma, including bland transarterial embolization, chemoembolization, radioembolization, and ablative therapies in conjunction as well as with systemic therapies, with a focus on combination therapies, patient selection, procedural technique, periprocedural management, and outcomes. Our findings suggest that LRT combined with systemic therapies is a viable strategy for improving progression-free survival and time to progression for patients with intermediate-to-late-stage HCC. However, further investigation is required to refine treatment protocols and define patient cohorts that would benefit the most.
引用
收藏
页数:30
相关论文
共 50 条
  • [41] Locoregional Therapy Before Liver Transplantation for Hepatocellular Carcinoma
    Jiang, Nan
    Li, Xing
    Xing, Yan-Fang
    Qiao, Yi-Dan
    Chen, Jie
    HEPATOLOGY, 2019, 70 (04) : 1490 - 1491
  • [42] Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma
    Yoo, Eun Jin
    Shin, Hye Sun
    Kim, Seung Up
    Joo, Dong Jin
    Park, Jun Yong
    Choi, Gi Hong
    Kim, Do Young
    Ahn, Sang Hoon
    Seong, Jinsil
    Koh, Myung Joo
    Han, Kwang-Hyub
    Chon, Chae Yoon
    ONCOTARGETS AND THERAPY, 2013, 6 : 755 - 759
  • [43] Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma
    Wang, Hui
    Liu, Ying
    Wang, Xiu
    Liu, Donghui
    Sun, Zhiqiang
    Wang, Chun
    Jin, Gang
    Zhang, Beiguang
    Yu, Shilong
    CANCER, 2015, 121 (17) : 2917 - 2925
  • [44] Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy
    Poon, RTP
    Fan, ST
    O'Suilleabhain, CB
    Wong, J
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2002, 195 (03) : 311 - 318
  • [45] Modified transarterial chemoembolization with locoregional administration of sorafenib for treating hepatocellular carcinoma: feasibility, efficacy, and safety in the VX-2 rabbit liver tumor model
    Seidensticker, Max
    Streit, Sebastian
    Nass, Norbert
    Wybranski, Christian
    Juergens, Julian
    Brauner, Jan
    Schulz, Nadine
    Kalinski, Thomas
    Seidensticker, Ricarda
    Garlipp, Benjamin
    Steffen, Ingo
    Ricke, Jens
    Dudeck, Oliver
    DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, 2016, 22 (04): : 378 - 384
  • [46] Combined locoregional treatment of patients with hepatocellular carcinoma: state of the art
    Iezzi, Roberto
    Pompili, Maurizio
    Posa, Alessandro
    Coppola, Giuseppe
    Gasbarrini, Antonio
    Bonomo, Lorenzo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (06) : 1935 - 1942
  • [47] Novel Therapy for Hepatocellular Carcinoma: Immunotherapy
    Jones, Patricia D.
    Gmunder, Kristin
    McLaughlin, Jeremy
    Martin, Paul M.
    Herrera, Cristina
    Feun, Lynn
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S624 - S625
  • [48] Combined locoregional treatment of patients with hepatocellular carcinoma: state of the art
    Roberto Iezzi
    Maurizio Pompili
    Alessandro Posa
    Giuseppe Coppola
    Antonio Gasbarrini
    Lorenzo Bonomo
    World Journal of Gastroenterology, 2016, 22 (06) : 1935 - 1942
  • [49] Combined anti hormonal therapy in cirrhotic patients with hepatocellular carcinoma (HCC) not suitable for surgical or locoregional therapy.
    Barone, M
    Vinciguerra, V
    Covello, SF
    Panella, C
    Augello, G
    Ladisa, R
    Francavilla, A
    GASTROENTEROLOGY, 1997, 112 (04) : A1220 - A1220
  • [50] Safety and effectiveness of tumor treating fields combined with sorafenib in preclinical models of hepatocellular carcinoma
    Davidi, S.
    Tempel-Brami, C.
    Munster, M.
    Gotlib, K.
    Zeevi, E.
    Schneiderman, R.
    Voloshin, T.
    Giladi, M.
    Weinberg, U.
    Palti, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S175 - S175